96829-58-2 Orlistat AKSci K744
 
 
Loading Please Wait...
  K744    AKSci Reference Standard
Orlistat
, >98%, powder
 
Tetrahydrolipstatin
N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
(2S)-1-[(2S,3S)-3-Hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate




IDENTITY
CAS Number:96829-58-2
MDL Number:MFCD05662360
MF:C29H53NO5
MW:495.73
BRN:3658031
SPECIFICATIONS & PROPERTIES
Purity:>98%, powder
Spectra:LCMS, Polarimetry
Physical Form:White to off-white crystalline powder or powder
Melting Point:42-47°C
Optical Rotation:-33 - -36° (c=1, CHCl3)
Long-Term Storage:Store long-term at 2-8°C

BIOLOGICAL INFO
Application(s):Lipase inhibitor
Form:Free base

REVIEW

 Orlistat is a drug designed to treat obesity. Orlistat works by inhibiting gastric and pancreatic lipases, the enzymes that break down triglycerides in the intestine. When lipase activity is blocked, triglycerides from the diet are not hydrolyzed into absorbable free fatty acids, and are excreted undigested instead.

REFERENCES
[1]Smith TJ, Crombie A, Sanders LF, Sigrist LD, Bathalon GP, McGraw S, Young AJ (2012). Efficacy of orlistat 60 mg on weight loss and body fat mass in US Army soldiers. J Acad Nutr Diet. 112(4):533-40. PMID 22717217.
[2] Gelebart P, Zak Z, Anand M, Belch A, Lai R (2012). Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS One. 7(4):e33738. PMID 22485149.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of June 3, 2020

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use.
Not for human use.


CATEGORIES

 APIs and Bioactives > Weight Control


PubChem